Further analysis revealed the prognostic value of IGFBP5 in ovarian cancer was more significant in patients receiving paclitaxel or paclitaxel and carboplatin combination therapy than carboplatin as a monotherapy, indicating that IGFBP5 may play a role in therapeutic responses to microtubule-stabilizing agents used to treat ovarian cancer (62). This evidence concerns the gene IGFBP5 and ovarian cancer.